BNR
Burning Rock Biotech LtdNASDAQHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$175.50M
P/E Ratio
—
EPS
$-0.74
Beta
1.60
52W High
$41.72
52W Low
$2.18
50-Day MA
$25.38
200-Day MA
$15.33
Dividend Yield
—
Profit Margin
-10.30%
Forward P/E
—
PEG Ratio
—
About Burning Rock Biotech Ltd
Burning Rock Biotech Limited primarily develops and provides screening tests for cancer therapies in the People's Republic of China. The company is headquartered in Guangzhou, China.
Fundamentals
| Revenue (TTM) | $539.57M |
| Gross Profit (TTM) | $402.91M |
| EBITDA | $-3.46M |
| Operating Margin | -9.53% |
| Return on Equity | -9.92% |
| Return on Assets | -4.02% |
| Revenue/Share (TTM) | $50.03 |
| Book Value | $7.43 |
| Price-to-Book | 2.25 |
| Price-to-Sales (TTM) | 0.33 |
| EV/Revenue | 1.415 |
| EV/EBITDA | -0.17 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.20% |
| Shares Outstanding | $9.03M |
| Float | $29.18M |
| % Insiders | 3.92% |
| % Institutions | 45.23% |
Data last updated: 4/7/2026